In der Zeit vom 23.12.24 bis zum 1.1.25 sind keine Bestellungen möglich.
  • Ruxolitinib in GvHD (RIG) stud...
  • Holdings

Result: Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

Title:
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Involved:
Bubnoff, Nikolas von (Verfasser) ; Ihorst, Gabriele (Verfasser) ; Grishina, Olga (Verfasser) ; Röthling, Nadine (Verfasser) ; Bertz, Hartmut (Verfasser) ; Duyster, Justus (Verfasser) ; Finke, Jürgen (Verfasser) ; Zeiser, Robert (Verfasser) 
Published:
Freiburg : Universität, 2019
Scope:
Online-Ressource
Format:
eBook
Language:
English
Subject Added Keywords:
DOI:
10.1186/s12885-018-5045-7

Additional information

Additional functions